about
The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders.Phase I trial of nelarabine in indolent leukemias.Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemiaSplenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation.Practical management of myelofibrosis with ruxolitinib.Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyCytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemiaB-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)Investigational Janus kinase inhibitors.A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphomaFludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.Leukaemic subtype of marginal zone lymphoma: a presentation of three cases and literature review.The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cellsAnte-mortem diagnosis of localized invasive esophageal aspergillosis in a patient with acute myeloid leukemia.Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaThe BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsAutologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma.Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia.New angles of attack in the fight against chronic lymphocytic leukemia: the advent of novel non-chemotherapeutic agents.Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia.Peripheral T cell and natural killer (NK) T cell lymphomas: a clinicopathological study from a single Australian centre.Out of sight, out of mind: an audit of inferior vena cava filter insertion and clinical follow up in an Australian institution and literature review.Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis.The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review.Src family kinases and their role in hematological malignancies.How applicable is fludarabine, cyclophosphamide and rituximab to the elderly?Survey of antifungal prophylaxis and fungal diagnostic tests employed in malignant haematology and haemopoietic stem cell transplantation (HSCT) in Australia and New Zealand.Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014.Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia.Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.The oral iron chelator deferasirox inhibits NF-κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia.Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era.Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib.
P50
Q33371973-D495220A-CBDE-4B11-AFF6-E8BD66F3FC77Q33378808-30F0421F-E196-4D72-A2E1-D5DABA734640Q33382608-67A9C62D-9CE2-44D1-998A-00FA85D05045Q33406990-665994BC-1EC1-419B-82E7-A87742E07685Q33428259-14A60A4A-FAC6-4217-BE32-8DBF6D74D892Q33437577-E93D6658-52C7-4DEB-B5AA-33CC45F5520BQ33438428-458248FE-25F8-4DED-A420-BBA71E912EB1Q33910990-63FF7C89-FFBB-48D9-82C0-C1EDD3AE5E2EQ34048170-56771F63-4C23-494A-AB3C-D649960FA281Q34052075-F49A4A45-7895-4071-8148-9C1615362652Q34508322-70B729D1-5BC1-4559-9D32-72192981BAACQ34648724-0C57A309-6F0C-4929-A4D8-F4AD9E7F24BCQ35678403-2A11C6A0-B2C1-44AC-837A-1E148535A07AQ35771157-C3E493B4-4759-4349-BAA4-09B09CC705E2Q35782582-EF27CE20-DC40-47B2-9BAE-67D6BF8108D3Q36165173-1E724320-F091-4859-8A95-AF76BA2556D3Q36194619-B28B3777-7F8C-401D-84BC-3325978D8CE2Q36490049-CC5F68B0-1B42-408C-9152-473FD8857B82Q37035832-998B264C-2F60-4719-A058-7E1ACCF71110Q37035925-BA8BED9C-0C2C-405D-A3B4-4F6AFE5BA7F0Q37499211-05CCEDBE-24B4-4E90-B04E-01A37D7E7D2EQ37509428-4FF92A29-DAC0-483A-8B04-79A18D2EE983Q37534547-CB3AFD33-AB94-4B08-AFA4-1DD991569632Q37623386-5CD74717-B5F1-4CB9-86A9-00D324A8F80FQ37710733-726B9787-39FF-402E-B0A0-F2AE6CD5760FQ37767703-D3E685E1-C2A0-4986-B470-5ADB598F3D14Q38008448-7FDE394F-9A06-4939-8536-2A8CE92392D2Q38020233-4415AFBB-36D6-471C-9EA5-A0799C9148FCQ38023536-3C541985-3302-4087-A7A5-1A5224EDA293Q38106512-E34A3431-3ECD-468A-A6C5-16D808C55741Q38203924-4A56B448-9F62-4208-8298-8FC8323283AFQ38217719-ABB9279E-8718-463C-BCC8-AEEFB275F07EQ38248474-6FCADD98-16B5-48ED-AA86-E9A3C3A50D41Q38284453-6F740D46-3D08-4A38-9F13-0ECEE7CDC6AAQ38284455-77E018E7-B135-41B4-BE75-BF7353D79BDDQ38797088-1B649962-857F-4B2E-84BA-9E6534C5B719Q38843190-6A7C6CBE-B5EB-44C1-A869-5F325E15B321Q38951695-85CFC348-7F03-4B0D-9630-2DD9E30F0B76Q39303082-E4D8F3EC-964B-4743-8FF8-079EE73D715AQ39306435-892F0936-4D48-4BA3-848F-FC78B8BBB461
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Constantine S. Tam
@ast
Constantine S. Tam
@en
Constantine S. Tam
@es
Constantine S. Tam
@nl
Constantine S. Tam
@sl
type
label
Constantine S. Tam
@ast
Constantine S. Tam
@en
Constantine S. Tam
@es
Constantine S. Tam
@nl
Constantine S. Tam
@sl
prefLabel
Constantine S. Tam
@ast
Constantine S. Tam
@en
Constantine S. Tam
@es
Constantine S. Tam
@nl
Constantine S. Tam
@sl
P106
P1153
7201444704
P31
P496
0000-0002-9759-5017